Irinotecan for Metastatic Gastric Cancer
Author Information
Author(s): Köhne C-H, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Betta D Di, Jacques C, Wilke H J
Primary Institution: Robert Rossle Klinik, Charité University Hospital, Berlin, Germany
Hypothesis
Does irinotecan improve response rates in chemotherapy naive patients with metastatic gastric adenocarcinoma?
Conclusion
Irinotecan shows activity in treating metastatic gastric cancer, with a response rate of 20% and manageable side effects.
Supporting Evidence
- Irinotecan showed a response rate of 20% in evaluable patients.
- Two complete responses and five partial responses were observed.
- The median survival time was 7.1 months.
- Neutropenia was the most common severe side effect.
- Patients experienced a median of 3 treatment cycles.
Takeaway
This study tested a medicine called irinotecan on patients with stomach cancer that hadn't been treated before, and it helped some of them feel better.
Methodology
Phase II trial with 40 patients receiving irinotecan every 3 weeks, assessing response rates and safety.
Potential Biases
Potential selection bias due to nonrandomized design.
Limitations
The study was nonrandomized and had a small sample size.
Participant Demographics
40 patients, 70% male, median age 58 years.
Statistical Information
P-Value
0.05
Confidence Interval
95% CI: 8.4-36.9%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website